Levine D, Ramsay L, Auty R, Branch R, Tidd M
Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):381-6. doi: 10.1007/BF00606552.
The pharmacological activity of single oral doses of a new aldosterone antagonist, prorenoate potassium, has been compared with spironolactone and placebo in a balanced double-blind crossover study in six healthy subject. Endogenous mineralocorticoids were stimulated by administration of frusemide followed by dietary sodium restriction, and the urinary excretion of electrolytes in response to prorenoate potassium, spironolactone and placebo was measured over a 24 hour period. Significant activity of prorenoate potassium and spironolactone was observed between 2 - 24 hours after medication, with peak activity at 6 - 8 hours. The active drugs significantly increased sodium excretion and the sodium : potassium (Na/K) ratio, but changes in potassium excretion were not significant. The total urine Na/K response to prorenoate potassium 45 mg was significantly greater than to spironolactone 100 mg.
在一项针对六名健康受试者的平衡双盲交叉研究中，将一种新型醛固酮拮抗剂——普乐瑞诺酸钾单次口服剂量的药理活性与螺内酯及安慰剂进行了比较。通过给予速尿并随后限制饮食中的钠来刺激内源性盐皮质激素，然后在24小时内测量普乐瑞诺酸钾、螺内酯和安慰剂作用下电解质的尿排泄情况。用药后2至24小时观察到普乐瑞诺酸钾和螺内酯有显著活性，在6至8小时达到活性峰值。活性药物显著增加了钠排泄及钠钾比，但钾排泄的变化不显著。45毫克普乐瑞诺酸钾的总尿钠钾反应显著大于100毫克螺内酯。
